Alliance for Pandemic Preparedness

June 11, 2020

Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19 A Multicenter Cohort Study

Category:

Topic:

  • [pre-print, not peer reviewed] Martinez-Sanz et al. conducted a cohort study of 1,229 patients with COVID-19 in Spain to determine the relationship between tocilizumab use and ICU admission or death. Tocilizumab was associated with decreased risk of death (aHR=0.34, 95%CI 0.16-0.72) and ICU admission or death (0.38, 0.19-0.81; p=0.011) among patients with high C–reactive protein (CRP) levels (>150 mg/L). There was no association with low rates of death or ICU admission among those with CRP £150 mg/L. 

Martinez-Sanz et al. (June 9, 2020). Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19 A Multicenter Cohort Study. Pre-print downloaded June 11 from https://doi.org/10.1101/2020.06.08.20125245